INC04 Unlocking the Potential of OX40 Ligand Pathway in AD: Targeting the Inflammatory Prequel
DESCRIPTION
In this industry-supported non-CME program, Dr Eric Simpson, Dr Alexandra Golant, and Dr Peter Lio will guide an interactive investigative quest focused on the OX40 ligand pathway in atopic dermatitis (AD). This unique symposium format integrates interactive challenges, progressively unveiling insights across key thematic modules. The program will dive deep into unmet needs in the heterogeneous population of patients with AD, highlighting the role of the OX40 ligand pathway in the underlying pathophysiology of AD, and why targeting the inflammatory prequel is important. Our experts will also explore the newly available Phase 3 data for amlitelimab. This program will emphasize the role of the OX40 ligand pathway and how targeted therapies could potentially bridge the treatment gap for patients with AD.
Speakers:
Dr. Eric Simpson, MD, MCR
Dr. Alexandra Golant, MD
Dr. Peter Lio, MD
6:30 PM Registration | 7:00 PM - 9:00 PM PROGRAM
Where: Crystal Ballroom - Embassy Suites Denver Convention Center
Presented by: Sanofi
Save this program to your schedule in the AAD Meeting App!
LEARNING OBJECTIVES
Discuss unmet needs in the heterogeneous population of patients with AD
Highlight the importance of the OX40 ligand pathway in driving the inflammatory prequel of AD
Explore future treatment goals in AD, including sustained efficacy off-therapy, and explore the most recent amlitelimab Phase 3 data in AD